Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$1.29.

  • Ensysce Biosciences' EPS (Basic) fell 22900.0% to -$1.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4, marking a year-over-year increase of 9175.68%. This contributed to the annual value of -$11.45 for FY2024, which is 8373.85% up from last year.
  • Ensysce Biosciences' EPS (Basic) amounted to -$1.29 in Q3 2025, which was down 22900.0% from -$0.79 recorded in Q2 2025.
  • Ensysce Biosciences' 5-year EPS (Basic) high stood at $1.0 for Q3 2024, and its period low was -$61.58 during Q3 2022.
  • Moreover, its 5-year median value for EPS (Basic) was -$3.35 (2024), whereas its average is -$12.28.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 9682795.55% in 2022, then soared by 21494.25% in 2024.
  • Over the past 5 years, Ensysce Biosciences' EPS (Basic) (Quarter) stood at -$9.33 in 2021, then crashed by 228.94% to -$30.69 in 2022, then rose by 24.35% to -$23.22 in 2023, then soared by 77.99% to -$5.11 in 2024, then skyrocketed by 74.75% to -$1.29 in 2025.
  • Its EPS (Basic) was -$1.29 in Q3 2025, compared to -$0.79 in Q2 2025 and -$1.39 in Q1 2025.